Rigel Pharmaceuticals Inc (NASDAQ: RIGL), South San Francisco, CA – FDA Inspections
Inspection records and compliance data for Rigel Pharmaceuticals Inc in South San Francisco, California. 4 FDA inspections on record, last inspected March 28, 2025. Publicly traded as NASDAQ: RIGL.
This profile covers Rigel Pharmaceuticals Inc based in South San Francisco, California, United States.
FDA Inspection History
- FDA inspections
- 4
- OAI
- 0
- VAI
- 0
- NAI
- 2
- Unclassified
- 2
- Form 483s
- 0
- Warning letters
- 0
First inspected August 23, 2017. Last inspected March 28, 2025.
FDA inspections (4)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| March 28, 2025 | Not classified | Human Drugs | 1265843 |
| September 28, 2022 | NAI | Human Drugs · Bioresearch Monitoring | 1191864 |
| December 8, 2017 | Not classified | Human Drugs | 1035429 |
| August 23, 2017 | NAI | Human Drugs · Bioresearch Monitoring | 1028212 |
No Form 483s, Warning Letters or EIRs on record.
Companies with similar regulatory profiles, compliance history, and operations.
Name
Rigel Pharmaceuticals Inc
Stock ticker
RIGL
Exchange
NASDAQ
Share price
$45.40
Market cap
$848.1M
Price as of
November 6, 2026
FEI Number
3004865166
Address
611 Gateway Blvd Ste 900, South San Francisco, California 94080, United States
Country
United States
ID: d9eb0a68-bb3f-4db0-86ac-6e28322ce2b6